Genomic Score Predicts Patients' Progression to Multiple Myeloma

Genomic score predicts patients' progression to multiple myeloma

A new risk assessment score developed by researchers at Dana-Farber Cancer Institute, the Broad Institute of MIT and Harvard, and Massachusetts General Hospital reveals how multiple myeloma, a form of blood cancer, begins and progresses from precancerous to malignant states by tracing DNA mutations.

U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma

ODAC recommendation based on the positive progression-free survival and clinical benefit in the Phase 3 AQUILA study

FDA Advisory Committee Votes 6-2 to Approve First-Ever Treatment Preventing Multiple Myeloma Progression

ODAC backs breakthrough therapy that could prevent multiple myeloma progression. First potential treatment for high-risk SMM shows promising trial results. Get details.

ODAC Votes 6-2 For Benefit-Risk Profile of SQ Daratumumab in High-Risk Smoldering Multiple Myeloma

Based on the trial population and end point criteria, ODAC voted for daratumumab and hyaluronidase-fijh injection for SQ use in high-risk smoldering multiple myeloma.